SEMAGLUTIDE: A POTENTIAL WEIGHT LOSS DRUG FOR OBESE PATIENTS
DOI:
https://doi.org/10.69723/njms.02.01.0315Abstract
Weight loss is difficult even when the obese/overweight individual is on a diet and exercise program. Clinical guidelines recommend supplementary pharmacotherapy, especially for adults with a BMI of 30 or higher or 27 or higher in those with coexis ng health condi ons. Nevertheless, using exis ng medications is restricted due to their effec veness, safety, and cost concerns.
Semaglutide is a glucagon-like pep de-1 (GLP-1) analog which has been permitted for treating type 2 diabetes in adults and reducing cardiovascular event risks. It is administered subcutaneously once a week at doses up to 1 mg.
Semaglutide has demonstrated weight reduc on effects in type 2 diabetes and obese patients participating in a phase 2 trial, which warranted further exploration.
References
Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract 2016; 22 Suppl 3: 1-203. 2016/05/25
Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H; Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402-24.
Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018 Mar;6(3):237-248.
Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, revised. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf
Wilding JPH, Baerham RL, Calanna S, Davies M, Van Gaal LF, LingvayI, etal. Once-Weekly Semaglude in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002
Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglude for the treatment of overweight and obesity: A review. Diabetes Obes Metab. 2023 Jan;25(1):18-35
Gao X, Hua X, Wang X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2022; 13: 935823. 2022/10/04
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Ayesha Khan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purposes. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
.png)
